TY - JOUR
T1 - Comparison of direct sequencing of the NS5B region with the Versant HCV genotype 2.0 assay for genotyping of viral isolates in Mexico
AU - Uribe-Noguez, Luis Antonio
AU - Mata-Marín, José Antonio
AU - Ocaña-Mondragón, Alicia
AU - Pompa-Mera, Ericka Nelly
AU - Ribas-Aparicio, Rosa María
AU - Arroyo-Anduiza, Carla Ileana
AU - Gomez-Torres, María Elena
AU - Chaparro-Sánchez, Alberto
AU - Gaytán-Martínez, Jesus
AU - Mauss, Stefan
N1 - Publisher Copyright:
© 2019 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases
PY - 2020/2
Y1 - 2020/2
N2 - Hepatitis C virus (HCV) infection affects an estimated 71 million people worldwide. HCV is classified into eight genotypes and >70 subtypes. Determination of HCV genotype is important for selection of type and duration of antiviral therapy, and genotype is also a predictor of treatment response. The most commonly used HCV genotyping method in clinical laboratories is a hybridization-based line probe assay (LiPA; Versant HCV Genotype 2.0). However, these methods have a lack of specificity in genotype identification and subtype assignment. Here, we compared the performance of Versant HCV Genotype 2.0 with the gold standard direct sequencing of the NS5B region, in 97 samples from Mexican patients. We found a genotypic concordance of 63.9% between these methods. While 68 samples (70%) were classified into HCV genotype 1 (GT1) by NS5B sequencing, it was not true for 17 samples (17.5%), which were not match HCV subtype by LiPA. Furthermore, nine of the 33 samples classified by NS5B sequencing as GT1a were not identified by LiPA. Use of direct sequencing could improve selection of the optimal therapy, avoid possible failures of therapy and avoid high costs resulting from incorrect genotyping tests in settings without broad access to pangenotypic regimens.
AB - Hepatitis C virus (HCV) infection affects an estimated 71 million people worldwide. HCV is classified into eight genotypes and >70 subtypes. Determination of HCV genotype is important for selection of type and duration of antiviral therapy, and genotype is also a predictor of treatment response. The most commonly used HCV genotyping method in clinical laboratories is a hybridization-based line probe assay (LiPA; Versant HCV Genotype 2.0). However, these methods have a lack of specificity in genotype identification and subtype assignment. Here, we compared the performance of Versant HCV Genotype 2.0 with the gold standard direct sequencing of the NS5B region, in 97 samples from Mexican patients. We found a genotypic concordance of 63.9% between these methods. While 68 samples (70%) were classified into HCV genotype 1 (GT1) by NS5B sequencing, it was not true for 17 samples (17.5%), which were not match HCV subtype by LiPA. Furthermore, nine of the 33 samples classified by NS5B sequencing as GT1a were not identified by LiPA. Use of direct sequencing could improve selection of the optimal therapy, avoid possible failures of therapy and avoid high costs resulting from incorrect genotyping tests in settings without broad access to pangenotypic regimens.
KW - Antiviral therapy
KW - Genotype
KW - Hepatitis C virus
KW - Hybridization-based line probe assay
KW - NS5B region
KW - Sequencing
UR - http://www.scopus.com/inward/record.url?scp=85072190051&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2019.08.009
DO - 10.1016/j.jiac.2019.08.009
M3 - Artículo
C2 - 31537472
AN - SCOPUS:85072190051
SN - 1341-321X
VL - 26
SP - 205
EP - 210
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 2
ER -